Revised Outcome of the Meeting of the Board of Directors of iSERA Lifesciences Limited (Formerly known as Covidh Technologies Limited) ('the Company') pursuant to Regulation 29 and 30 of ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
iSERA Lifesciences Limited's Board approved multiple key proposals on April 21, 2026. The authorised share capital will increase from Rs. 11 crore to Rs. 25 crore by creating 1.4 crore new equity shares. The company will acquire 100% of iSERA Biological Limited (a pharma/biotech firm) through a share swap - 1,61,82,800 shares at Rs. 48.20 per share, totaling Rs. 78 crore consideration. The swap ratio is 1:1 based on independent valuations. iSERA Biological had turnover of Rs. 18.36 crore in FY25 with EBITDA of Rs. 7.67 crore, growing significantly from Rs. 7.41 crore turnover in FY23. The new MOA and AOA will be adopted to align with Companies Act 2013. All proposals require shareholder approval via postal ballot.
This acquisition significantly expands iSERA Lifesciences into pharma/biotech. Existing shareholders will face dilution as 1.62 crore new shares are issued (promoters getting ~50% of new shares). The company gains a subsidiary with proven revenue growth. Shareholders should carefully review the related party transaction given promoter involvement.